心血管

订阅

MedSci主页 / 所有栏目 / 心血管

HRS/ACC/AHA关于在临床试验未纳入或不典型患者中ICD应用的共识声明

2014-05-14 相关专家组 医学论坛网

ICDHRS临床试验
关注

在美国心律学会年会(HRS 2014)召开之际，《心律学》(Heart Rhythm)杂志于5月9日在线发表了《HRS/美国心脏病学会(ACC)/美国心脏学会(AHA)关于在临床试验未纳入或不典型患者中ICD应用的共识声明》。 下载共识：HRS/美国心脏病学会(ACC)/美国心脏学会(AHA)关于在临床试验未纳入或不典型患者中ICD应用的共识声明 原始出处： Fred M. Ku

在美国心律学会年会(HRS 2014)召开之际，《心律学》(Heart Rhythm)杂志于5月9日在线发表了《HRS/美国心脏病学会(ACC)/美国心脏学会(AHA)关于在临床试验未纳入或不典型患者中ICD应用的共识声明》。


该共识主要关注以下可能自ICD获益的人群：非心肌梗死导致的肌钙蛋白水平改变;心肌梗死后40天内;血运重建后90天内;首次诊断非缺血性心肌病后9个月内。上述人群经常不被纳入随机临床试验，因此共识中的推荐意见并没有标注推荐级别。该共识的推荐意见主要是基于随机临床试验亚组分析、回顾性研究、大型登记研究分析以及专家意见。


下载共识：HRS/美国心脏病学会(ACC)/美国心脏学会(AHA)关于在临床试验未纳入或不典型患者中ICD应用的共识声明


原始出处：

Fred M. Kusumoto, Hugh Calkins, John Boehmer, Alfred E. Buxton, Mina K. Chung, Michael R. Gold, Stefan H. Hohnloser, Julia Indik, Richard Lee,  Mandeep R. Mehra, Venu Menon, Richard L. Page, Win-Kuang Shen, David J. Slotwiner, Lynne Warner Stevenson, Paul D. Varosy, Lisa Welikovitch.HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials.Heart Rhythm May 09, 2014 DOI: http://dx.doi.org/10.1016/j.hrthm.2014.03.041

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1860455, encodeId=fc031860455fd, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Mon Apr 20 22:13:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898614, encodeId=c4a618986145b, content=<a href='/topic/show?id=e5062028978' target=_blank style='color:#2F92EE;'>#不典型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20289, encryptionId=e5062028978, topicName=不典型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Sep 10 15:13:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267209, encodeId=110a126e209b8, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324933, encodeId=0dc313249335b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464101, encodeId=26ea1464101d1, content=<a href='/topic/show?id=da7d9119bc' target=_blank style='color:#2F92EE;'>#HRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9119, encryptionId=da7d9119bc, topicName=HRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=259a6588710, createdName=ysjykql, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=)]
    2015-04-20 yilong5287542

    #ICD#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1860455, encodeId=fc031860455fd, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Mon Apr 20 22:13:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898614, encodeId=c4a618986145b, content=<a href='/topic/show?id=e5062028978' target=_blank style='color:#2F92EE;'>#不典型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20289, encryptionId=e5062028978, topicName=不典型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Sep 10 15:13:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267209, encodeId=110a126e209b8, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324933, encodeId=0dc313249335b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464101, encodeId=26ea1464101d1, content=<a href='/topic/show?id=da7d9119bc' target=_blank style='color:#2F92EE;'>#HRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9119, encryptionId=da7d9119bc, topicName=HRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=259a6588710, createdName=ysjykql, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=)]
    2014-09-10 yaanren

    #不典型#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1860455, encodeId=fc031860455fd, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Mon Apr 20 22:13:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898614, encodeId=c4a618986145b, content=<a href='/topic/show?id=e5062028978' target=_blank style='color:#2F92EE;'>#不典型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20289, encryptionId=e5062028978, topicName=不典型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Sep 10 15:13:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267209, encodeId=110a126e209b8, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324933, encodeId=0dc313249335b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464101, encodeId=26ea1464101d1, content=<a href='/topic/show?id=da7d9119bc' target=_blank style='color:#2F92EE;'>#HRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9119, encryptionId=da7d9119bc, topicName=HRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=259a6588710, createdName=ysjykql, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=)]
    2014-05-16 zhaohui6731

    #AHA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1860455, encodeId=fc031860455fd, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Mon Apr 20 22:13:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898614, encodeId=c4a618986145b, content=<a href='/topic/show?id=e5062028978' target=_blank style='color:#2F92EE;'>#不典型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20289, encryptionId=e5062028978, topicName=不典型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Sep 10 15:13:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267209, encodeId=110a126e209b8, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324933, encodeId=0dc313249335b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464101, encodeId=26ea1464101d1, content=<a href='/topic/show?id=da7d9119bc' target=_blank style='color:#2F92EE;'>#HRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9119, encryptionId=da7d9119bc, topicName=HRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=259a6588710, createdName=ysjykql, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=)]
    2014-05-16 12498568m50暂无昵称

    #ACC#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1860455, encodeId=fc031860455fd, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Mon Apr 20 22:13:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898614, encodeId=c4a618986145b, content=<a href='/topic/show?id=e5062028978' target=_blank style='color:#2F92EE;'>#不典型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20289, encryptionId=e5062028978, topicName=不典型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Sep 10 15:13:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267209, encodeId=110a126e209b8, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324933, encodeId=0dc313249335b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464101, encodeId=26ea1464101d1, content=<a href='/topic/show?id=da7d9119bc' target=_blank style='color:#2F92EE;'>#HRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9119, encryptionId=da7d9119bc, topicName=HRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=259a6588710, createdName=ysjykql, createdTime=Fri May 16 01:13:00 CST 2014, time=2014-05-16, status=1, ipAttribution=)]
    2014-05-16 ysjykql

    #HRS#

    0

相关资讯

JAMA：单腔ICD植入用于无起搏器适应证患者一级预防优于双腔ICD

5月15日JAMA刊发的一项研究报告称，在接受可植入式埋藏式心律转复除颤器(ICD)用作一级预防的无起搏适应证患者人群中发现，与应用单腔ICD相比，双腔ICD没有表现出任何优势。 这项回顾性队列研究纳入了32,000余例美国患者，其植入单腔和双腔ICD患者的1年死亡率、心衰或全因住院率均未见显著差异。丹佛健康医学中心的Pamela N. Peterson博士及其同事报告称。然而，双腔ICD却存在

JACC：6分钟步行试验可确认ICD治疗无法获益患者

美国一项研究表明，利用基线6分钟步行试验(SMV)距离小于288米可确认无法从ICD治疗中获益并且胺碘酮治疗有害的亚组患者。论文于4月9日在线发表于《美国心脏病学会杂志》(J Am Coll Cardiol)。 SCD-HeFT试验显示NYHA III级患者未能从ICD中获益并且胺碘酮治疗可能有害，NYHA II级患者则可从ICD中得到显著生存获益，但尚不清楚是否存在更为客观的功能指标。此项研究

Heart：ICD置入者临床转归存在性别差异

　　荷兰一项研究表明，与男性相比，置入型心律转复除颤器（ICD）女性置入者的死亡率较低，并且适当ICD治疗倾向于较少。论文于5月30日在线发表于《心脏》（Heart）。 　　此项研究前瞻性人群研究共纳入1946例一级预防ICD置入患者，其中男、女性分别占79%和21%。主要转归指标为全因死亡、ICD治疗（抗心动过速起搏和电击）以及ICD电击。 　　结果显示，在中位随访3.3年期间，

去神经心肌可预测心脏猝死风险

据第18届世界心脏病大会(WCHD)上报告的一项历时4年的前瞻性观察性研究的结果，心脏病发作后的去神经心肌量可预测心脏猝死的几率及是否需要使用置入式除颤器(ICD)。这项研究旨在更好地预测除颤器的潜在受益者，其招募的患者大部分在基线时都已接受了初次血运重建，并且都符合使用除颤器的条件。总体而言，受试者年龄均在65岁左右，左室射血分数约为26%，NYHA心功能分级为Ⅱ级心力衰竭；人口学特征不因是否满

Heart Rhythm: ICD放电对成人先天性心脏病患者性功能的影响

随着植入式心脏转复除颤器（ICD）的问世，越来越多的成人先天性心脏病患者植入ICD用于心源性猝死的一级或二级预防，其主要原因包括越来越多的恶性心律失常被发现及ICD技术的日益成熟。法洛氏四联症患者是需要植入ICD的最大亚群，既往的临床研究已经涉及了ICD植入失败及ICD相关并发症的原因分析，约30%-40%的患者存在ICD的不正确放电。 虽然ICD放电可以拯救患者的生命，但是其带来的心理上的影响

Heart：ICD可为等待心脏移植者带来生存获益

瑞士一项研究表明，置入型心律转复除颤器（ICD）可对等待心脏移植的终末期心衰患者产生即刻和持续的生存益处。论文6月27日在线发表于《心脏》（Heart）。 此项研究共纳入1089例等待心脏移植的终末期心衰患者，其中550例（51%）接受ICD治疗，因心源性猝死一级和二级预防而置入者分别为216和334例。对置入和未置入ICD的患者进行全因死亡率对比。 结果显示，尽管心脏移植中位等待时间仅为8个